Language

Chinese English

Home page

CPIC 2026 | Full schedule release, China's annual new drug benchmark has arrived

Jul 03,2026

The global discourse power of new drugs has long been anchored in San Francisco. Nowadays, when Chinese pipelines and BD transactions dominate half of the world, the world urgently needs a strategic hub that is stationed in the East and connects the globe.

CPIC 2026， That's the answer.

From July 22nd to 24th, the Shanghai National Convention and Exhibition Center - this "four leaf clover" that has witnessed countless miracles - will create the ultimate home for the Chinese version of JPM under the name of "National New Drug". This is not a one-way 'internationalization', but the 'presence' of global forces.

✔ Global gathering, crossing mountains and seas

Core forces from four continents and fifteen countries gather: all five European countries have arrived, Lilly AZ、 Led by SVP of Bayer and Roche, the four multinational giants; Seven regions in Asia never fall, with heavyweight players such as Astellas, South Korean Biotech, Singapore, and Saudi Arabia entering the market; South American powers such as Brazil also broke the deadlock strongly.

✔ Penetrating the entire chain, shattering the dilemma

60+sessions, 600+topics, 800 speakers, and 40 technology tracks directly targeting global pain points. From BD going global, NewCo model to cross-border BD and mergers and acquisitions, from "selling seedlings" to "selling harvest", pricing power is discussed on site! The special sessions of China US, China Europe, China Japan, and "BRICS" allow global capital to gather here and initiate borderless business dialogue.

✔ The decision-making level is present, and all dimensions are in place

Academicians Xie Xiaoliang, Chen Kaixian and others lead the academic highland; Leading figures from industries such as Baekje, Kangfang, Baili Tianheng, and WuXi Biologics were all present; Huawei, Jingtai, Yingsi Intelligence and other AI new forces bring cutting-edge practices; Junlian, Ernst&Young, Fangda Law Firm and other capital full chain platforms; The top clinical PI authority is in charge.

When innovative elements intersect in the same field, Chinese new drugs will complete a closed loop from technical validation to commercialization on their own turf.

CPIC 2026 does not discuss whether China can innovate, but only answers core questions of common concern at home and abroad:

▪ How can China's efficiency accelerate global innovation?

▪ How can global capital seize the opportunities in China?

From July 22nd to 24th, at the Shanghai National Convention and Exhibition Center.

Let us witness together the arrival of a new era of new drugs in China!

Guiding Institutions：Shanghai Biopharmaceutical Technology Industry Promotion Center、Shanghai Center for Innovative Drug R&D、Shanghai Global Health Innovation Research Institute

Organizing Unit：Tonacea

Strategic Partners：School of Biotechnology, Fudan University、GPHL、WuXi AppTec、WuXi Biologics、Tofflon、Huawei Pharmaceutical BU、Ernst & Young、Fangda Partners、Legend Capital、China Chamber of Commerce for Import and Export of Medicines and Health Products、NECC(Shanghai)

25% off for the last 10 days!

Meeting Agenda

7月22日全天

金色大厅

主论坛：中国效率加速全球创新

大会揭幕仪式

大会致辞

颁奖仪式：CPIC创新药奖、全球合作奖

大会报告

谢晓亮：中国科学院院士，美国国家科学院外籍院士，昌平国家实验室主任

汪　来：百济神州总裁、全球研发负责人

夏　瑜：康方生物创始人、董事长

Stefan Platz：SVP，Clinical Pharmacology & SafetySciences,BioPharmaceuticals R&D, AstraZeneca

对话：百利天恒的MNC之路

朱　义（嘉宾）：百利天恒创始人、董事长

程增江（主持）：同写意创始人

发布：广药集团创新药开发战略

李小军：广药集团董事长

圆桌对话1：中国效能驱动MNC创新加速

孙勇奎：美国国家工程院院士，上海创新药物研发中心主任

吴晓滨：百济神州总裁兼首席运营官

沈　宏：罗氏中国创新中心负责人、全球高级副总裁

Stefan Platz：SVP，Clinical Pharmacology & SafetySciences,BioPharmaceuticals R&D, AstraZeneca

Kendra Rose：SVP and Global Head of BD&L - CGT, Cardiovascular and Immunology, Bayer Pharmaceuticals

Rogier Janssens：默克中国总裁，默克生命科学业务中国负责人

韩　亮：方达律师事务所管委会主任

☕️

中国创新药全球合作与交易观察

Daniel Mathews：安永全球生命科学行业合伙人

大规模CRDMO平台驱动持续高速增长

陈智胜：药明生物首席执行官，药明海德董事长，药明合联董事长

全球首个实体瘤CAR-T的开发与商业化

李宗海：科济药业董事长

中国生物药产业全球化路径

朱　迅：同写意新药英才俱乐部创始理事长

美国监管变局下的中国新药出海

何如意：上海全球健康创新研究院院长

圆桌对话2：中国创新药出海下一个五年

陈启宇：复星医药董事长

邱华伟：华润三九董事长

谢其润：中国生物制药董事会主席

葛均友：科伦博泰CEO

房健民：荣昌生物CEO

马　健：晶泰科技联合创始人、首席执行官

圆桌对话3：中国FIC/BIC新药如何改写全球临床用药指南

李　进：上海高博肿瘤医院院长

周彩存：上海市东方医院肿瘤科主任，国际肺癌研究协会主席

马　军：哈尔滨血液病肿瘤研究所原所长，CSCO监事会监事长

沈　琳：北京大学肿瘤医院原副院长、消化肿瘤内科主任

王　莉：礼来全球高级副总裁，礼来中国药物开发及医学事务中心负责人

圆桌对话4：中国生物科技全球化创新投资新趋势

许晨鸣：中信证券医疗组国际业务负责人

吕明方：中国医疗健康产业投资50人论坛创始主席，方源资本合伙人，上海医药集团原董事长

王俊峰：君联资本联席首席投资官、董事总经理

陈　宇：TCG Crossover（TCGX）创始人兼管理合伙人

孙佳林：中国医药创新促进会医药创新投资专业委员会副主任委员、高特佳投资集团总经理

以上为大会拟定日程，持续更新中......

4.2会馆

A1厅

◉ Non‑clinical Assessment of Novel High‑Potential Drugs（Co-organized: JOINN Laboratories）

◉ Nanobody Drug R&D Session（Co-organizer: Biointron）

◉ Decree No. 818 and a New Era for the Development of Biomedicine Industry session（Co-hosted: Tofflon）

◉ IIT Supervision Model and China’s Innovation Efficiency Session（Co-organized: Zhengzhou Airport Economy Zone Administrative Committee、WuXi ATU）

◉ Innovative Small Molecule Chemical Drugs Session（Co-Organizer：Genhouse Bio）

◉ Gene Therapy Innovation Session（Co-organizers : CoJourney）

< 左右滑动查看更多 >

A2厅

◉ Organoid and Biochip Session（Co-organizer: Xellar Biosystems）

◉ ATMP & CGT Global Expansion Session（Co-hosts: IASO Bio）

◉ Patient-Centric Stem Cell New Drug R&D Innovation Practice Session（Session Co-organizer: Guangzhou Cellgenes Biotechnology Co., Ltd.）

◉ Advanced Stem Cell Culture Technology Session（Co-hosted: Youyi Bio, JYSS Bio）

◉ Stem Cell and Regenerative Medicine New Technology Session（Co-hosted: Vcanbio Co-organized: Excell Bio）

◉ In-Vivo CAR-T and Cellular Therapy Session（Co-organizers : Juventas Cell Therapy, ProBio，ABclonal）

< 左右滑动查看更多 >

B1厅

◉ Breakthroughs in Next-Generation Innovative Therapies（Co-organizers: BrightGene ; Laurel Venture Capital）

◉ Breakthroughs in Next-Generation Innovative Therapies（Co-organizers : InnoStar,Tofflon, ChemPartner, GemPharmatech）

< 左右滑动查看更多 >

B2厅

◉ Global Innovation of Antibodies and ADCs session（Co-organizer: Altruist Biologics）

◉ CNS创新药研发专场（联合主办：瀚枢生物、夸克医药）CNS Novel Drug R&D Session

◉ Novel Anti-Tumor and Autoimmune Therapeutics Session

< 左右滑动查看更多 >

C1厅

◉ Computing Power × Mental Power × R&D Power: New Paradigms of Innovative Drug R&D in the AI Era Session（Co-host: Foxu.AI、Jeyou Pharma、Shanghai Academy of Clinical Innovation and Translational Science）

◉ AI Reshaping the End-to-End Clinical R&D Session（Co-host: Q2BI Clinical Research Institute）

◉ 智研未来专场-AI for life science and drug discoveryComputing Power × Mental Power × R&D Power: New Paradigms of Innovative Drug R&D in the AI Era Session（Session Co-organized by: MegaRobo）

◉ AI for Science Reshaping Innovative Drug R&D Session（Co-organizers : DP Technology）

◉ Roundtable: AI-Empowered Four-in-One Translation Platform

◉ AI-Driven Innovation Practices for Pharmaceutical Enterprises

◉ AI·Intelligent Transformation: From Data Foundation to Scenario Value（Session Co-organized by: Marathon Venture Partners）

< 左右滑动查看更多 >

C2厅

◉ The Booming Radiopharmaceuticals Session（Co-hosted: Baiyunshan Rare-Nuclear Health）

◉ WuXi AppTec Session（Co-hosted: WuXi AppTec）

◉ Peptide Drug R&D Frontier Session（Co-hosts: Revvity）

◉ Biomanufacturing Project Roadshow Session

◉ CPIC Roadshow Session

< 左右滑动查看更多 >

D1厅

◉ The Era of Superintelligent Agents for Chinese Innovative Drugs（Co-Organizer：Toursun Synbio）

◉ Building an Innovative Cooperation Ecosystem for the Biopharmaceutical Supply Chain（Co-hosted: Alioth Biotech (Shanghai) Co., Ltd. ）
◉ Antibody and ADC Drug Intelligent Manufacturing Session（Co-hosted: Jiangsu Hanbon Science & Technology Co., Ltd.）
◉ The Path to Innovation and Transformation for Traditional Pharmaceutical Companies（Co‑organizers:GPHL）
◉ Biosimilars Commercialization & Global Launch Session（China Focus）（Co-organized:Kexing Biopharma，Thousandoaks Biopharmaceuticals）
◉ Bio-Link Capital Roadshow Session（Co-organized by: Bio-Link Capital）

< 左右滑动查看更多 >

D2厅

◉ Empower Innovative Oncology Pipelines, Unlock Global Core Value of Early-Stage Clinical Assets（Co-hosted: Novotech）

◉ Biomedical M&A Session（Co-hosted: Morning Whistle Group）
◉ Global Development of Pharmaceutical Companies and Emerging Market Cooperation Session（Co-hosted: Rxilient & Legend Capital）
◉ Ecosystem Transformation of Biomedical Innovation
◉ Western Returned Scholars Association Session: Innovation, Translation and Global Competitiveness of Chinese Healthcare Institutions

< 左右滑动查看更多 >

E1厅

◉ Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises（Co-hosted: Fangda Partners）
◉ Protheragen Session: Global Biomedical Cross-Border Transactions（Co-hosted: Protheragen）
◉ China’s Innovative Drugs and Capital Market Session（Co-hosted: Soochow Securities）
◉ From IP to BD: China Innovative Drug Transaction Competency（Co-host: Merits & Tree Law Offices）
◉ Collaboration Between North American and Chinese Innovative Drug Industries（Session Co-Organizer：Beijing Boyinuo Technology）

< 左右滑动查看更多 >

E2厅

◉ （联合主办：C50、康希诺生物、同写意）Deepening the Footprint in Global Emerging Markets to Deliver Full-Chain Value of Chinese Innovative Drugs（Co-hosts: C50, CanSino Biologics，TONACEA）

◉ The Evolution and Beyond of NewCo Session
◉ Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3（Session Co-Organizer：Bank of Jiangsu、Norstella）
◉ Capital Strategies and Hong Kong IPOs for Biopharmaceutical Enterprises

< 左右滑动查看更多 >

G厅

◉ Innovations in Exosome Therapeutics Session

◉ Industrial Securities Session（Co-hosted:Industrial Securities）

◉ Brain-Computer Interface Session （Session Co-organizers: NeuroXess,Triwise Capital）

◉ International Advanced Drug Delivery Systems / Drug-Device Combinations Session（Organizer: ESC MedTech, Supporting Units: Wanhai Medical, Aptar Pharma）

◉ Biopharmaceutical Industrial Park Development Session

◉ Vaccine Innovation and Global Expansion

◉ USTC/China‑Japan Pharmaceuticals&New Materials Innovation Session – Original Innovation Power from USTC（Co-organized by: Intellective Bio、OureGenAI、Perkins Coie LLP）

< 左右滑动查看更多 >

丝路厅

◉ Hong Kong Global Opportunities Session（Co-hosted: HONG KONG CHINESE INDUSTRY & COMMERCE ASSOCIATION、HK Bio-Med Innotech Association）

◉ China-Europe Healthcare Industry Session（Co-hosted: French Healthcare Alliance，TONACEA Co-organized:genOway-SH，EBT）

◉ China–U.S. Collaboration Forum: Accelerating Global Drug Development Through Chinese Innovation（Co-hosted:Uni-Pioneers，Co-organized: GB-Partner）

◉ Cross-border Investment Session
◉ China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
◉ Workshop: The Key to Win Biotech Global BD Deals（Co-organized: BridgeBio Global）